Immunic, INC Form 4 insider transactions

Elena Ridloff, a Director of Immunic, Inc., received 50,740 shares of common stock on August 6, 2026.

Director Simona Skerjanec acquired 25,370 stock options in IMMUNIC, Inc. (IMUX) with an exercise price of $14.80, vesting over one year.

Richard Alan Rudick, a Director at IMMUNIC, INC., acquired 25,370 stock options on July 5, 2026, as detailed in a Form 4 filing.

Director Barclay Phillips of IMMUNIC, Inc. acquired 25,370 stock options with an exercise price of $14.80, vesting over one year.

IMMUNIC, INC. Director Joerg Neermann reported the acquisition of stock options on July 5, 2026, as part of his compensation.

IMMUNIC, INC. reports that Director Jon Congleton acquired 25,370 stock options on July 5, 2026, as part of a vesting schedule.

Director Jon Congleton of IMMUNIC, Inc. has acquired 50,740 stock options, as detailed in a recent SEC Form 4 filing.

IMMUNIC, INC. reports that Director Simona Skerjanec acquired 25,370 stock options on June 29, 2026, as part of a plan approved by the Board and stockholders.

Richard Alan Rudick, a Director at IMMUNIC, INC., acquired 25,370 stock options on June 29, 2026, as detailed in a Form 4 filing.

IMMUNIC, INC. reports that Director Tamar Howson acquired 25,370 stock options on June 29, 2026, as part of a plan approved by the Board of Directors and stockholders.

IMMUNIC, INC. reports that Director Joerg Neermann acquired 25,370 stock options on June 29, 2026, following stockholder approval of an equity incentive plan amendment.

Director Barclay Phillips reported the acquisition of stock options for 25,370 shares of IMMUNIC, Inc. common stock.

IMMUNIC, INC. reports a stock option grant to President and COO Jason Tardio, subject to stockholder approval.

IMMUNIC, INC. reports that Director Daniel Vitt acquired 445,000 stock options on June 29, 2026, following stockholder approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan.

Director Michael W. Bonney acquired 100,000 stock options for IMMUNIC, INC. (IMUX) on June 29, 2026, as part of a plan approved by the Board of Directors and stockholders.

Immunic, Inc. CEO Erik Lundgren was granted 1,000,000 stock options with an exercise price of $13.05.

Michael A. Panzara, Chief Medical Officer of IMMUNIC, INC., acquired 300,000 stock options.

IMMUNIC, INC.'s Chief Financial Officer, Glenn Whaley, was granted 1.96 million Stock Appreciation Rights with an exercise price of $0.77, exercisable from August 1, 2026, subject to specific conditions.

IMMUNIC, INC. Executive Chairman Duane Nash was granted 2,205,000 Stock Appreciation Rights with an exercise price of $0.77, exercisable from August 1, 2026, subject to certain conditions.

IMMUNIC, Inc. CEO Daniel Vitt was granted 6.02 million Stock Appreciation Rights with an exercise price of $0.77, contingent on future corporate actions and shareholder approval.

IMMUNIC, INC.'s Chief Medical Officer, Andreas Muehler, was granted 2,310,000 Stock Appreciation Rights (SARs) with an exercise price of $0.77, exercisable from August 1, 2026, subject to various conditions.

IMMUNIC, Inc.'s President and COO, Jason Tardio, acquired 2,310,000 Stock Appreciation Rights with an exercise price of $0.77, exercisable from August 1, 2026, subject to various conditions including warrant exercises and private placement tranches.

IMMUNIC, Inc.'s President and COO, Jason Tardio, filed an amended Form 4 to correct an administrative error regarding a stock option grant, also confirming a recent purchase of common stock.

IMMUNIC, INC.'s Chief Financial Officer, Glenn Whaley, filed an amended Form 4 to correct an administrative error regarding the number of stock options granted.

IMMUNIC, Inc.'s CEO and Director, Daniel Vitt, filed an amended Form 4 to correct an administrative error regarding the number of stock options granted, confirming a grant of 1,558,000 options.

IMMUNIC, Inc.'s Executive Chairman, Duane Nash, filed an amended Form 4 to correct an administrative error regarding the number of stock options granted on June 5, 2025.

IMMUNIC, INC.'s Chief Medical Officer, Andreas Muehler, filed an amended Form 4 to correct the reported number of stock options granted, now totaling 598,500 shares.

IMMUNIC, Inc. Executive Chairman Duane Nash has increased his direct beneficial ownership in the company by purchasing 20,000 shares of common stock.

IMMUNIC, Inc. Executive Chairman Duane Nash was granted 560,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, INC.'s Chief Medical Officer, Andreas Muehler, was granted 595,000 stock options with an exercise price of $0.7729, vesting over four years.